Vimarsana
Biggest News Aggregation in the World

Page 21 - Oncology Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Oncology Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Oncology Program Today - Breaking & Trending Today

Adolescent and young adult leukemia survivors have reduced long-term survival compared to peers without cancer - Vimarsana News

Adolescent and young adult leukemia survivors have reduced long-term survival compared to peers without cancer

Researchers at The University of Texas MD Anderson Cancer Center have discovered that adolescent and young adult (AYA) cancer survivors of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) have reduced long-term survival rates compared to their peers without cancer.

New cancer diagnosis associated with risk for fatal, nonfatal cardiovascular events - Vimarsana News

New cancer diagnosis associated with risk for fatal, nonfatal cardiovascular events

New cancer diagnosis appeared associated with increased risk for cardiovascular death, as well as incident heart failure, stroke or pulmonary embolism, according to a retrospective cohort study published in JACC: CardioOncology.“This risk persisted to at least 7 years from cancer diagnosis and appeared most pronounced in patients with hematologic, gastrointestinal, genitourinary and

Source: healio.com
Social Workers Help Patients Find Light After Cancer Diagnosis - Vimarsana News

Social Workers Help Patients Find Light After Cancer Diagnosis

The UK Markey Cancer Center’s Psych-Oncology Program includes a comprehensive support network to walk alongside patients and caregivers alike during a challenging cancer journey.

Source: uky.edu
NeuBase Therapeutics Reports Business Update and Financial - Vimarsana News

NeuBase Therapeutics Reports Business Update and Financial

Investigational New Drug (IND)-enabling studies for the myotonic dystrophy type 1 (DM1) program development candidate continue as planned; invited to...

A2 Bio to Present at ASCO-GI 2022 on Use of Next Generation Sequencing (NGS) to Identify GI Cancer Patients for Future Tmod™ CAR T Therapy - Vimarsana News

A2 Bio to Present at ASCO-GI 2022 on Use of Next Generation Sequencing (NGS) to Identify GI Cancer Patients for Future Tmod™ CAR T Therapy

/PRNewswire/ -- A2 Biotherapeutics, Inc. ("A2 Bio") is a biotechnology company focused on the development of a first-in-class, logic-gated Tmod™ CAR T cell...